

"Express Mail" mailing label number EL 856 112 375 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on 6-11-01

By: Nancy RamosPrinted: Nancy Ramos**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Lal et al.

Title: HUMAN PHOSPHOLIPID BINDING PROTEINS

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in application Serial No. 09/390,126, filed September 3, 1999, which is a divisional of application Serial No. 09/208,718, filed December 9, 1998, issued on May 16, 2000 as U.S. Patent No. 6,063,767, which is a divisional of application Serial No. 08/958,820, filed October 28, 1997, issued March 30, 1999 as U.S. Patent No. 5,888,742, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are

inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.


It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.




Richard C. Ekstrom

Reg. No. 37,027

Direct Dial Telephone: (650) 843-7352

Date: 11 June 2001



Michelle M. Stempien

Reg. No. 41,327

Direct Dial Telephone: (650) 843-7219

Date: 11 June 2001

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.
	PF-0397-3 CON	To Be Assigned
	Applicants	
(Use several sheets if necessary)	Lal et al.	
	Filing Date	Group
	Herewith	To Be Assigned

U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,658,877	08/19/97	Tsao	514	2	
	2	5,225,537	07/06/93	Foster	530	380	

Foreign Patent Documents

							Translation	
		Document	Date	Country	Class	Subclass	Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Wirtz, K.W.A., "Phospholipid Transfer Proteins", <u>Annu. Rev. Biochem.</u> , 60: 73-99 (1991)
2	Geijtenbeek, T.B.H. et al., "cDNA cloning and tissue-specific expression of the phosphatidylcholine transfer protein gene", <u>Biochem. J.</u> , 316: 49-55 (1996) (GI 897693)
3	Teerlink, T. et al., "Tissue Distribution And Subcellular Localization Of Phosphatidylcholine Transfer Protein In Rats As Determined By Radioimmunoassay", <u>Biochim. Biophys. Acta</u> , 713: 61-67 (1982)
4	Smit, J.J.M. et al., "Homozygous Disruption of the Murine <i>mdr2</i> P-Glycoprotein Gene Leads to a Complete Absence of Phospholipid from Bile and to Liver Disease", <u>Cell</u> , 75: 451-462 (1993)
5	Exton, J.H., "Phosphatidylcholine breakdown and signal transduction", <u>Biochim. Biophys. Acta</u> , 1212: 26-42 (1994)
6	Hristova, K. et al., "Critical Role of Lipid Composition in Membrane Permeabilization by Rabbit Neutrophil Defensins", <u>J. Biol. Chem.</u> , 272: 24224-24233 (1997)
7	Pavlinova, L.I. et al., "Role Of The Phosphoinositide Signal System And Methylation Of Phosphatidylethanolamine In The Development Of Long-Term Post-Tetanic Potentiation In Rats", <u>Neurosci. Behav. Physiol.</u> 27: 234-239 (1997)
8	James, P.F. and R.A. Zoeller, "Isolation of Animal Cell Mutants Defective in Long-chain Fatty Aldehyde Dehydrogenase", <u>J. Biol. Chem.</u> , 272: 23532-23529 (1997)
9	Hori, N. et al., "A human cDNA sequence homologue of bovine phosphatidylethanolamine-binding protein", <u>Gene</u> , 140: 293-294 (1994)

Examiner

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			

[illegible]

Examiner

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation of not in conformance and not considered. Include copy of this form with your communication to applicant.